<DOC>
	<DOC>NCT00539448</DOC>
	<brief_summary>Primary objective : To evaluate the efficacy (in terms of change in HbA1c readings starting from baseline then after 13 weeks &amp; at the end of the study which will be after 26 weeks) in subjects with type I diabetes mellitus. Secondary objective : - Recording the average daily dose of both insulin Glulisine &amp; insulin Glargine in type I DM. - Recording adverse events.</brief_summary>
	<brief_title>Gulf, Lantus, Apidra Evaluation in Type 1 Diabetics Study</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 1</mesh_term>
	<mesh_term>Insulin, Globin Zinc</mesh_term>
	<mesh_term>Insulin glulisine</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>Newly diagnosed type I diabetic patients Type I diabetes treated with basalbolus regimen including 3 or more injections of Regular Human Insulin per day BMI, 2640 kg/m2 HbA1c, 7.5%10% Median 2Hrs post prandial more than or equal to 140 mg/dl (more than or equal to 7.8 mmol/L) FPG more than or equal to 120 mg/dl (more than or equal to 6.7 mmol/L) Willingness to accept, and ability to inject insulin Glargine therapy Pregnancy : The use of LANTUS &amp; APIDRA during pregnancy is not contraindicated. However, in the absence of supportive data, Sanofi Aventis Pharmaceuticals cannot specifically recommend the use of Lantus in this patient population The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>September 2009</verification_date>
</DOC>